Drugs / RENORAL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03807583 | Mar 2019 → Jan 2020 | end stage renal failure | Indigo Therapeutics | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RENORAL | “The product under study RENORAL® is notified to the DGCCRF with the status of food supplement for medical purposes (FSMP) and specific for renal insufficiency.” NCT03807583 ↗1“The product under study RENORAL® is notified to the DGCCRF with the status of food supplement for medical purposes (FSMP) and specific for renal insufficiency.” NCT03807583 ↗ |
| Route | Oral | “administration per os of Renoral” NCT03807583 ↗ |